| June 30, | |||||||||||
(in thousands) | 2026 | 2025 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 16,032\u00a0 | $ | 32,400\u00a0 | |||||||
Restricted cash - current | 4,686\u00a0 | 3,333\u00a0 | |||||||||
Total current assets | 20,718\u00a0 | 35,733\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 959\u00a0 | 1,333\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 21,677\u00a0 | $ | 37,066\u00a0 |
| Computer hardware | 3 years | ||||
| Machinery and equipment | 2 - 25 years | ||||
| Automobiles | 5 years | ||||
| Leasehold improvements | Shorter of lease period or useful life | ||||
| Furniture and fixtures | 7 years |
| June 30, | |||||||||||
(in thousands) | 2026 | 2025 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 16,032\u00a0 | $ | 32,400\u00a0 | |||||||
Restricted cash - current | 4,686\u00a0 | 3,333\u00a0 | |||||||||
Total current assets | 20,718\u00a0 | 35,733\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 959\u00a0 | 1,333\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 21,677\u00a0 | $ | 37,066\u00a0 |
| June 30, | |||||||||||
(in thousands) | 2026 | 2025 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 16,032\u00a0 | $ | 32,400\u00a0 | |||||||
Restricted cash - current | 4,686\u00a0 | 3,333\u00a0 | |||||||||
Total current assets | 20,718\u00a0 | 35,733\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 959\u00a0 | 1,333\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 21,677\u00a0 | $ | 37,066\u00a0 |
| Computer hardware | 3 years | ||||
| Machinery and equipment | 2 - 25 years | ||||
| Automobiles | 5 years | ||||
| Leasehold improvements | Shorter of lease period or useful life | ||||
| Furniture and fixtures | 7 years |
| Computer hardware | 3 years | ||||
| Machinery and equipment | 2 - 25 years | ||||
| Automobiles | 5 years | ||||
| Leasehold improvements | Shorter of lease period or useful life | ||||
| Furniture and fixtures | 7 years |
(in thousands) | 2026 | 2025 | |||||||||
| Computer hardware | $ | 18,745\u00a0 | $ | 17,680\u00a0 | |||||||
Machinery and equipment(1) | 20,133\u00a0 | 18,239\u00a0 | |||||||||
| Leasehold improvements | 17,413\u00a0 | 17,390\u00a0 | |||||||||
| Furniture and fixtures | 4,671\u00a0 | 4,671\u00a0 | |||||||||
| Work in progress | 259\u00a0 | 229\u00a0 | |||||||||
| Total | 61,221\u00a0 | 58,209\u00a0 | |||||||||
Less accumulated depreciation(2) | (49,171) | (43,632) | |||||||||
| Property and equipment\u2014net | $ | 12,050\u00a0 | $ | 14,577\u00a0 |
| Year Ended June 30, | |||||||||||||||||
(in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
| Senior: | |||||||||||||||||
| Medicare advantage commissions | $ | 510,810\u00a0 | $ | 518,031\u00a0 | $ | 569,648\u00a0 | |||||||||||
Other Senior commissions | 17,390\u00a0 | 11,397\u00a0 | 11,237\u00a0 | ||||||||||||||
| Other services | 47,747\u00a0 | 70,965\u00a0 | 74,964\u00a0 | ||||||||||||||
| Total Senior revenue | 575,947\u00a0 | 600,393\u00a0 | 655,849\u00a0 | ||||||||||||||
| Healthcare Services: | |||||||||||||||||
| Pharmacy | 830,854\u00a0 | 728,753\u00a0 | 464,853\u00a0 | ||||||||||||||
| Other services | 14,081\u00a0 | 13,952\u00a0 | 13,655\u00a0 | ||||||||||||||
| Total Healthcare Services revenue | 844,935\u00a0 | 742,705\u00a0 | 478,508\u00a0 | ||||||||||||||
| Life: | |||||||||||||||||
| Term commissions | 80,045\u00a0 | 74,685\u00a0 | 73,980\u00a0 | ||||||||||||||
| Final expense commissions | 85,019\u00a0 | 78,175\u00a0 | 64,138\u00a0 | ||||||||||||||
| Other services | 20,975\u00a0 | 20,118\u00a0 | 19,812\u00a0 | ||||||||||||||
| Total Life revenue | 186,039\u00a0 | 172,978\u00a0 | 157,930\u00a0 | ||||||||||||||
| All other: | |||||||||||||||||
| Commissions | 18,540\u00a0 | 17,308\u00a0 | 35,244\u00a0 | ||||||||||||||
| Other services | 1,687\u00a0 | 718\u00a0 | 984\u00a0 | ||||||||||||||
Total All other revenue | 20,227\u00a0 | 18,026\u00a0 | 36,228\u00a0 | ||||||||||||||
| Eliminations: | |||||||||||||||||
| Commissions | (3,603) | (3,339) | (2,567) | ||||||||||||||
| Other services | (5,046) | (4,169) | (4,172) | ||||||||||||||
| Total Elimination revenue | (8,649) | (7,508) | (6,739) | ||||||||||||||
| Total Commissions and other services revenue | 787,645\u00a0 | 797,841\u00a0 | 856,923\u00a0 | ||||||||||||||
| Total Pharmacy revenue | 830,854\u00a0 | 728,753\u00a0 | 464,853\u00a0 | ||||||||||||||
| Total Revenue | $ | 1,618,499\u00a0 | $ | 1,526,594\u00a0 | $ | 1,321,776\u00a0 |
| (in thousands) | ||||||||
| Balance as of June\u00a030, 2024 | $ | 881,317\u00a0 | ||||||
Commission revenue from revenue recognized | 317,787\u00a0 | |||||||
| Net commission revenue adjustment from change in estimate | (4,468) | |||||||
| Amounts recognized as accounts receivable, net | (243,808) | |||||||
Balance as of June\u00a030, 2025 | $ | 950,828\u00a0 | ||||||
| Commission revenue from revenue recognized | 281,490\u00a0 | |||||||
| Net commission revenue adjustment from change in estimate | 22,167\u00a0 | |||||||
| Amounts recognized as accounts receivable, net | (263,082) | |||||||
Balance as of June\u00a030, 2026 | $ | 991,403\u00a0 |
| (in thousands) | ||||||||
| Balance as of June\u00a030, 2024 | $ | 8,066\u00a0 | ||||||
| Commission and other services revenue recognized | (34,808) | |||||||
| Amounts recognized as contract liabilities | 27,440\u00a0 | |||||||
Balance as of June\u00a030, 2025 | $ | 698\u00a0 | ||||||
| Commission and other services revenue recognized | (13,438) | |||||||
| Amounts recognized as contract liabilities | 13,639\u00a0 | |||||||
Balance as of June\u00a030, 2026 | $ | 899\u00a0 |
| Year Ended June 30, | |||||||||||||||||
(in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
| Senior: | |||||||||||||||||
| Medicare advantage commissions | $ | 510,810\u00a0 | $ | 518,031\u00a0 | $ | 569,648\u00a0 | |||||||||||
Other Senior commissions | 17,390\u00a0 | 11,397\u00a0 | 11,237\u00a0 | ||||||||||||||
| Other services | 47,747\u00a0 | 70,965\u00a0 | 74,964\u00a0 | ||||||||||||||
| Total Senior revenue | 575,947\u00a0 | 600,393\u00a0 | 655,849\u00a0 | ||||||||||||||
| Healthcare Services: | |||||||||||||||||
| Pharmacy | 830,854\u00a0 | 728,753\u00a0 | 464,853\u00a0 | ||||||||||||||
| Other services | 14,081\u00a0 | 13,952\u00a0 | 13,655\u00a0 | ||||||||||||||
| Total Healthcare Services revenue | 844,935\u00a0 | 742,705\u00a0 | 478,508\u00a0 | ||||||||||||||
| Life: | |||||||||||||||||
| Term commissions | 80,045\u00a0 | 74,685\u00a0 | 73,980\u00a0 | ||||||||||||||
| Final expense commissions | 85,019\u00a0 | 78,175\u00a0 | 64,138\u00a0 | ||||||||||||||
| Other services | 20,975\u00a0 | 20,118\u00a0 | 19,812\u00a0 | ||||||||||||||
| Total Life revenue | 186,039\u00a0 | 172,978\u00a0 | 157,930\u00a0 | ||||||||||||||
| All other: | |||||||||||||||||
| Commissions | 18,540\u00a0 | 17,308\u00a0 | 35,244\u00a0 | ||||||||||||||
| Other services | 1,687\u00a0 | 718\u00a0 | 984\u00a0 | ||||||||||||||
Total All other revenue | 20,227\u00a0 | 18,026\u00a0 | 36,228\u00a0 | ||||||||||||||
| Eliminations: | |||||||||||||||||
| Commissions | (3,603) | (3,339) | (2,567) | ||||||||||||||
| Other services | (5,046) | (4,169) | (4,172) | ||||||||||||||
| Total Elimination revenue | (8,649) | (7,508) | (6,739) | ||||||||||||||
| Total Commissions and other services revenue | 787,645\u00a0 | 797,841\u00a0 | 856,923\u00a0 | ||||||||||||||
| Total Pharmacy revenue | 830,854\u00a0 | 728,753\u00a0 | 464,853\u00a0 | ||||||||||||||
| Total Revenue | $ | 1,618,499\u00a0 | $ | 1,526,594\u00a0 | $ | 1,321,776\u00a0 |
| (in thousands) | ||||||||
| Balance as of June\u00a030, 2024 | $ | 881,317\u00a0 | ||||||
Commission revenue from revenue recognized | 317,787\u00a0 | |||||||
| Net commission revenue adjustment from change in estimate | (4,468) | |||||||
| Amounts recognized as accounts receivable, net | (243,808) | |||||||
Balance as of June\u00a030, 2025 | $ | 950,828\u00a0 | ||||||
| Commission revenue from revenue recognized | 281,490\u00a0 | |||||||
| Net commission revenue adjustment from change in estimate | 22,167\u00a0 | |||||||
| Amounts recognized as accounts receivable, net | (263,082) | |||||||
Balance as of June\u00a030, 2026 | $ | 991,403\u00a0 |
| (in thousands) | ||||||||
| Balance as of June\u00a030, 2024 | $ | 8,066\u00a0 | ||||||
| Commission and other services revenue recognized | (34,808) | |||||||
| Amounts recognized as contract liabilities | 27,440\u00a0 | |||||||
Balance as of June\u00a030, 2025 | $ | 698\u00a0 | ||||||
| Commission and other services revenue recognized | (13,438) | |||||||
| Amounts recognized as contract liabilities | 13,639\u00a0 | |||||||
Balance as of June\u00a030, 2026 | $ | 899\u00a0 |
(in thousands) | 2026 | 2025 | |||||||||
| Computer hardware | $ | 18,745\u00a0 | $ | 17,680\u00a0 | |||||||
Machinery and equipment(1) | 20,133\u00a0 | 18,239\u00a0 | |||||||||
| Leasehold improvements | 17,413\u00a0 | 17,390\u00a0 | |||||||||
| Furniture and fixtures | 4,671\u00a0 | 4,671\u00a0 | |||||||||
| Work in progress | 259\u00a0 | 229\u00a0 | |||||||||
| Total | 61,221\u00a0 | 58,209\u00a0 | |||||||||
Less accumulated depreciation(2) | (49,171) | (43,632) | |||||||||
| Property and equipment\u2014net | $ | 12,050\u00a0 | $ | 14,577\u00a0 |
(in thousands) | 2026 | 2025 | |||||||||
| Software | $ | 32,535\u00a0 | $ | 28,306\u00a0 | |||||||
| Work in progress | 621\u00a0 | 18\u00a0 | |||||||||
| Total | 33,156\u00a0 | 28,324\u00a0 | |||||||||
Less accumulated amortization(1) | (15,084) | (13,264) | |||||||||
| Software\u2014net | $ | 18,072\u00a0 | $ | 15,060\u00a0 |
(in thousands) | 2026 | 2025 | |||||||||
| Software | $ | 32,535\u00a0 | $ | 28,306\u00a0 | |||||||
| Work in progress | 621\u00a0 | 18\u00a0 | |||||||||
| Total | 33,156\u00a0 | 28,324\u00a0 | |||||||||
Less accumulated amortization(1) | (15,084) | (13,264) | |||||||||
| Software\u2014net | $ | 18,072\u00a0 | $ | 15,060\u00a0 |
| (in thousands) | Balance Sheet Classification | 2026 | 2025 | ||||||||||||||
| Assets | |||||||||||||||||
| Operating leases | Operating lease right-of-use assets | $ | 20,511\u00a0 | $ | 24,635\u00a0 | ||||||||||||
| Finance leases | 1,485\u00a0 | 1,552\u00a0 | |||||||||||||||
| Total lease right-of-use assets | $ | 21,996\u00a0 | $ | 26,187\u00a0 | |||||||||||||
| Liabilities | |||||||||||||||||
| Current | |||||||||||||||||
| Operating leases | Operating lease liabilities\u2013current | $ | 4,448\u00a0 | $ | 4,820\u00a0 | ||||||||||||
| Finance leases | 615\u00a0 | 400\u00a0 | |||||||||||||||
| Non-current | |||||||||||||||||
| Operating leases | Operating lease liabilities | 21,753\u00a0 | 25,982\u00a0 | ||||||||||||||
| Finance leases | 1,032\u00a0 | 1,200\u00a0 | |||||||||||||||
| Total lease liabilities | $ | 27,848\u00a0 | $ | 32,402\u00a0 |
| Year Ended June 30, | |||||||||||
| (in thousands) | 2026 | 2025 | |||||||||
Finance lease costs(1) | $ | 874\u00a0 | $ | 577\u00a0 | |||||||
Operating lease costs(2) | 7,577\u00a0 | 7,383\u00a0 | |||||||||
| Short-term lease costs | 266\u00a0 | 251\u00a0 | |||||||||
Variable lease costs(3) | 768\u00a0 | 609\u00a0 | |||||||||
| Sublease income | (2,038) | (2,225) | |||||||||
| Total net lease costs | $ | 7,447\u00a0 | $ | 6,595\u00a0 |
| Year Ended June 30, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||||||||||||||
| (in thousands) | Operating leases | Finance leases | Total | Operating leases | Finance leases | Total | |||||||||||||||||||||||||||||
| Cash paid for amounts included in measurement of liabilities: | |||||||||||||||||||||||||||||||||||
| Operating cash flows from leases | $ | 8,056\u00a0 | $ | 251\u00a0 | $ | 8,307\u00a0 | $ | 8,145\u00a0 | $ | 176\u00a0 | $ | 8,321\u00a0 | |||||||||||||||||||||||
| Financing cash flows from leases | \u2014 | 527\u00a0 | 527\u00a0 | \u2014\u00a0 | 327\u00a0 | 327\u00a0 | |||||||||||||||||||||||||||||
| Right-of-use assets obtained in exchange for new lease liabilities | $ | \u2014\u00a0 | $ | 569\u00a0 | $ | 569\u00a0 | $ | 5,093\u00a0 | $ | 1,731\u00a0 | $ | 6,824\u00a0 |
| Year Ended June 30, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Operating leases | Finance leases | Operating leases | Finance leases | ||||||||||||||||||||
| Weighted-average remaining lease term (in years) | 6.01 | 2.61 | 6.41 | 3.65 | |||||||||||||||||||
| Weighted-average discount rate | 12.85\u00a0 | % | 12.73\u00a0 | % | 12.61\u00a0 | % | 14.22\u00a0 | % |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| 2027 | $ | 7,268\u00a0 | $ | 785\u00a0 | $ | 8,053\u00a0 | ||||||||||||||
| 2028 | 6,906\u00a0 | 709\u00a0 | 7,615\u00a0 | |||||||||||||||||
| 2029 | 7,006\u00a0 | 417\u00a0 | 7,423\u00a0 | |||||||||||||||||
| 2030 | 4,615\u00a0 | 30\u00a0 | 4,645\u00a0 | |||||||||||||||||
| 2031 | 4,259\u00a0 | \u2014\u00a0 | 4,259\u00a0 | |||||||||||||||||
| Thereafter | 8,726\u00a0 | \u2014\u00a0 | 8,726\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 38,780\u00a0 | 1,941\u00a0 | 40,721\u00a0 | |||||||||||||||||
| Less: interest | 12,579\u00a0 | 294\u00a0 | 12,873\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 26,201\u00a0 | $ | 1,647\u00a0 | $ | 27,848\u00a0 |
| (in thousands) | Total | |||||||
| 2027 | $ | 2,102\u00a0 | ||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| 2030 | 161\u00a0 | |||||||
| Total sublease income | $ | 6,125\u00a0 |
| (in thousands) | Balance Sheet Classification | 2026 | 2025 | ||||||||||||||
| Assets | |||||||||||||||||
| Operating leases | Operating lease right-of-use assets | $ | 20,511\u00a0 | $ | 24,635\u00a0 | ||||||||||||
| Finance leases | 1,485\u00a0 | 1,552\u00a0 | |||||||||||||||
| Total lease right-of-use assets | $ | 21,996\u00a0 | $ | 26,187\u00a0 | |||||||||||||
| Liabilities | |||||||||||||||||
| Current | |||||||||||||||||
| Operating leases | Operating lease liabilities\u2013current | $ | 4,448\u00a0 | $ | 4,820\u00a0 | ||||||||||||
| Finance leases | 615\u00a0 | 400\u00a0 | |||||||||||||||
| Non-current | |||||||||||||||||
| Operating leases | Operating lease liabilities | 21,753\u00a0 | 25,982\u00a0 | ||||||||||||||
| Finance leases | 1,032\u00a0 | 1,200\u00a0 | |||||||||||||||
| Total lease liabilities | $ | 27,848\u00a0 | $ | 32,402\u00a0 |
| Year Ended June 30, | |||||||||||
| (in thousands) | 2026 | 2025 | |||||||||
Finance lease costs(1) | $ | 874\u00a0 | $ | 577\u00a0 | |||||||
Operating lease costs(2) | 7,577\u00a0 | 7,383\u00a0 | |||||||||
| Short-term lease costs | 266\u00a0 | 251\u00a0 | |||||||||
Variable lease costs(3) | 768\u00a0 | 609\u00a0 | |||||||||
| Sublease income | (2,038) | (2,225) | |||||||||
| Total net lease costs | $ | 7,447\u00a0 | $ | 6,595\u00a0 |
| Year Ended June 30, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||||||||||||||
| (in thousands) | Operating leases | Finance leases | Total | Operating leases | Finance leases | Total | |||||||||||||||||||||||||||||
| Cash paid for amounts included in measurement of liabilities: | |||||||||||||||||||||||||||||||||||
| Operating cash flows from leases | $ | 8,056\u00a0 | $ | 251\u00a0 | $ | 8,307\u00a0 | $ | 8,145\u00a0 | $ | 176\u00a0 | $ | 8,321\u00a0 | |||||||||||||||||||||||
| Financing cash flows from leases | \u2014 | 527\u00a0 | 527\u00a0 | \u2014\u00a0 | 327\u00a0 | 327\u00a0 | |||||||||||||||||||||||||||||
| Right-of-use assets obtained in exchange for new lease liabilities | $ | \u2014\u00a0 | $ | 569\u00a0 | $ | 569\u00a0 | $ | 5,093\u00a0 | $ | 1,731\u00a0 | $ | 6,824\u00a0 |
| Year Ended June 30, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Operating leases | Finance leases | Operating leases | Finance leases | ||||||||||||||||||||
| Weighted-average remaining lease term (in years) | 6.01 | 2.61 | 6.41 | 3.65 | |||||||||||||||||||
| Weighted-average discount rate | 12.85\u00a0 | % | 12.73\u00a0 | % | 12.61\u00a0 | % | 14.22\u00a0 | % |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| 2027 | $ | 7,268\u00a0 | $ | 785\u00a0 | $ | 8,053\u00a0 | ||||||||||||||
| 2028 | 6,906\u00a0 | 709\u00a0 | 7,615\u00a0 | |||||||||||||||||
| 2029 | 7,006\u00a0 | 417\u00a0 | 7,423\u00a0 | |||||||||||||||||
| 2030 | 4,615\u00a0 | 30\u00a0 | 4,645\u00a0 | |||||||||||||||||
| 2031 | 4,259\u00a0 | \u2014\u00a0 | 4,259\u00a0 | |||||||||||||||||
| Thereafter | 8,726\u00a0 | \u2014\u00a0 | 8,726\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 38,780\u00a0 | 1,941\u00a0 | 40,721\u00a0 | |||||||||||||||||
| Less: interest | 12,579\u00a0 | 294\u00a0 | 12,873\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 26,201\u00a0 | $ | 1,647\u00a0 | $ | 27,848\u00a0 |
| (in thousands) | Total | |||||||
| 2027 | $ | 2,102\u00a0 | ||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| 2030 | 161\u00a0 | |||||||
| Total sublease income | $ | 6,125\u00a0 |
| (in thousands) | Balance Sheet Classification | 2026 | 2025 | ||||||||||||||
| Assets | |||||||||||||||||
| Operating leases | Operating lease right-of-use assets | $ | 20,511\u00a0 | $ | 24,635\u00a0 | ||||||||||||
| Finance leases | 1,485\u00a0 | 1,552\u00a0 | |||||||||||||||
| Total lease right-of-use assets | $ | 21,996\u00a0 | $ | 26,187\u00a0 | |||||||||||||
| Liabilities | |||||||||||||||||
| Current | |||||||||||||||||
| Operating leases | Operating lease liabilities\u2013current | $ | 4,448\u00a0 | $ | 4,820\u00a0 | ||||||||||||
| Finance leases | 615\u00a0 | 400\u00a0 | |||||||||||||||
| Non-current | |||||||||||||||||
| Operating leases | Operating lease liabilities | 21,753\u00a0 | 25,982\u00a0 | ||||||||||||||
| Finance leases | 1,032\u00a0 | 1,200\u00a0 | |||||||||||||||
| Total lease liabilities | $ | 27,848\u00a0 | $ | 32,402\u00a0 |
| Year Ended June 30, | |||||||||||
| (in thousands) | 2026 | 2025 | |||||||||
Finance lease costs(1) | $ | 874\u00a0 | $ | 577\u00a0 | |||||||
Operating lease costs(2) | 7,577\u00a0 | 7,383\u00a0 | |||||||||
| Short-term lease costs | 266\u00a0 | 251\u00a0 | |||||||||
Variable lease costs(3) | 768\u00a0 | 609\u00a0 | |||||||||
| Sublease income | (2,038) | (2,225) | |||||||||
| Total net lease costs | $ | 7,447\u00a0 | $ | 6,595\u00a0 |
| Year Ended June 30, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||||||||||||||
| (in thousands) | Operating leases | Finance leases | Total | Operating leases | Finance leases | Total | |||||||||||||||||||||||||||||
| Cash paid for amounts included in measurement of liabilities: | |||||||||||||||||||||||||||||||||||
| Operating cash flows from leases | $ | 8,056\u00a0 | $ | 251\u00a0 | $ | 8,307\u00a0 | $ | 8,145\u00a0 | $ | 176\u00a0 | $ | 8,321\u00a0 | |||||||||||||||||||||||
| Financing cash flows from leases | \u2014 | 527\u00a0 | 527\u00a0 | \u2014\u00a0 | 327\u00a0 | 327\u00a0 | |||||||||||||||||||||||||||||
| Right-of-use assets obtained in exchange for new lease liabilities | $ | \u2014\u00a0 | $ | 569\u00a0 | $ | 569\u00a0 | $ | 5,093\u00a0 | $ | 1,731\u00a0 | $ | 6,824\u00a0 |
| Year Ended June 30, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Operating leases | Finance leases | Operating leases | Finance leases | ||||||||||||||||||||
| Weighted-average remaining lease term (in years) | 6.01 | 2.61 | 6.41 | 3.65 | |||||||||||||||||||
| Weighted-average discount rate | 12.85\u00a0 | % | 12.73\u00a0 | % | 12.61\u00a0 | % | 14.22\u00a0 | % |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| 2027 | $ | 7,268\u00a0 | $ | 785\u00a0 | $ | 8,053\u00a0 | ||||||||||||||
| 2028 | 6,906\u00a0 | 709\u00a0 | 7,615\u00a0 | |||||||||||||||||
| 2029 | 7,006\u00a0 | 417\u00a0 | 7,423\u00a0 | |||||||||||||||||
| 2030 | 4,615\u00a0 | 30\u00a0 | 4,645\u00a0 | |||||||||||||||||
| 2031 | 4,259\u00a0 | \u2014\u00a0 | 4,259\u00a0 | |||||||||||||||||
| Thereafter | 8,726\u00a0 | \u2014\u00a0 | 8,726\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 38,780\u00a0 | 1,941\u00a0 | 40,721\u00a0 | |||||||||||||||||
| Less: interest | 12,579\u00a0 | 294\u00a0 | 12,873\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 26,201\u00a0 | $ | 1,647\u00a0 | $ | 27,848\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| 2027 | $ | 7,268\u00a0 | $ | 785\u00a0 | $ | 8,053\u00a0 | ||||||||||||||
| 2028 | 6,906\u00a0 | 709\u00a0 | 7,615\u00a0 | |||||||||||||||||
| 2029 | 7,006\u00a0 | 417\u00a0 | 7,423\u00a0 | |||||||||||||||||
| 2030 | 4,615\u00a0 | 30\u00a0 | 4,645\u00a0 | |||||||||||||||||
| 2031 | 4,259\u00a0 | \u2014\u00a0 | 4,259\u00a0 | |||||||||||||||||
| Thereafter | 8,726\u00a0 | \u2014\u00a0 | 8,726\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 38,780\u00a0 | 1,941\u00a0 | 40,721\u00a0 | |||||||||||||||||
| Less: interest | 12,579\u00a0 | 294\u00a0 | 12,873\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 26,201\u00a0 | $ | 1,647\u00a0 | $ | 27,848\u00a0 |
| (in thousands) | Total | |||||||
| 2027 | $ | 2,102\u00a0 | ||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| 2030 | 161\u00a0 | |||||||
| Total sublease income | $ | 6,125\u00a0 |
| 2026 | 2025 | ||||||||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Impairment Charges | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||||||||||||||||||||
| Customer relationships | $ | 1,423\u00a0 | $ | (1,409) | $ | 14\u00a0 | $ | 17,492\u00a0 | $ | (4,209) | $ | (13,252) | $ | 31\u00a0 | |||||||||||||||||||||||||||
| Trade name | \u2014\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 2,680\u00a0 | \u2014\u00a0 | (2,680) | \u2014\u00a0 | ||||||||||||||||||||||||||||||||||
| Proprietary software | 4,342\u00a0 | (3,517) | 825\u00a0 | 4,342\u00a0 | \u2014\u00a0 | (2,418) | 1,924\u00a0 | ||||||||||||||||||||||||||||||||||
| Non-compete agreements | 100\u00a0 | (100) | \u2014\u00a0 | 100\u00a0 | \u2014\u00a0 | (82) | 18\u00a0 | ||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | 5,865\u00a0 | $ | (5,026) | $ | 839\u00a0 | $ | 24,614\u00a0 | $ | (4,209) | $ | (18,432) | $ | 1,973\u00a0 | |||||||||||||||||||||||||||
| Proprietary Software | Non-compete agreements | Customer relationships | Total | ||||||||||||||||||||
| 2027 | 825\u00a0 | \u2014\u00a0 | 14\u00a0 | 839\u00a0 | |||||||||||||||||||
| Total | $ | 825\u00a0 | $ | \u2014\u00a0 | $ | 14\u00a0 | $ | 839\u00a0 |
| 2026 | 2025 | ||||||||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Impairment Charges | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||||||||||||||||||||
| Customer relationships | $ | 1,423\u00a0 | $ | (1,409) | $ | 14\u00a0 | $ | 17,492\u00a0 | $ | (4,209) | $ | (13,252) | $ | 31\u00a0 | |||||||||||||||||||||||||||
| Trade name | \u2014\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 2,680\u00a0 | \u2014\u00a0 | (2,680) | \u2014\u00a0 | ||||||||||||||||||||||||||||||||||
| Proprietary software | 4,342\u00a0 | (3,517) | 825\u00a0 | 4,342\u00a0 | \u2014\u00a0 | (2,418) | 1,924\u00a0 | ||||||||||||||||||||||||||||||||||
| Non-compete agreements | 100\u00a0 | (100) | \u2014\u00a0 | 100\u00a0 | \u2014\u00a0 | (82) | 18\u00a0 | ||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | 5,865\u00a0 | $ | (5,026) | $ | 839\u00a0 | $ | 24,614\u00a0 | $ | (4,209) | $ | (18,432) | $ | 1,973\u00a0 | |||||||||||||||||||||||||||
| Proprietary Software | Non-compete agreements | Customer relationships | Total | ||||||||||||||||||||
| 2027 | 825\u00a0 | \u2014\u00a0 | 14\u00a0 | 839\u00a0 | |||||||||||||||||||
| Total | $ | 825\u00a0 | $ | \u2014\u00a0 | $ | 14\u00a0 | $ | 839\u00a0 |
| (in thousands) | 2026 | 2025 | |||||||||
Term Loan | $ | 322,969\u00a0 | $ | \u2014\u00a0 | |||||||
Previous Term Loans | \u2014\u00a0 | 314,000\u00a0 | |||||||||
Class A Notes | 38,336\u00a0 | 50,054\u00a0 | |||||||||
Class B Notes | 25,558\u00a0 | 33,369\u00a0 | |||||||||
| Unamortized debt issuance costs and debt discount | (16,695) | (12,311) | |||||||||
| Total debt | 370,168\u00a0 | 385,112\u00a0 | |||||||||
| Less current portion of long-term debt: | (22,014) | (68,523) | |||||||||
| Long-term debt | $ | 348,154\u00a0 | $ | 316,589\u00a0 |
| (in thousands) | 2027 | 2028 | 2029 | 2030 | 2031 | Total | ||||||||||||||||||||||||||||||||
Term Loan | $ | 8,125\u00a0 | $ | 14,219\u00a0 | $ | 16,250\u00a0 | $ | 16,250\u00a0 | $ | 268,125\u00a0 | $ | 322,969\u00a0 | ||||||||||||||||||||||||||
| Class A Notes | 10,592\u00a0 | 8,650\u00a0 | 19,094\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 38,336\u00a0 | ||||||||||||||||||||||||||||||||
| Class B Notes | 7,062\u00a0 | 5,767\u00a0 | 12,729\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 25,558\u00a0 | ||||||||||||||||||||||||||||||||
| Total obligations | $ | 25,779\u00a0 | $ | 28,636\u00a0 | $ | 48,073\u00a0 | $ | 16,250\u00a0 | $ | 268,125\u00a0 | $ | 386,863\u00a0 |
| (in thousands) | 2026 | 2025 | |||||||||
Term Loan | $ | 322,969\u00a0 | $ | \u2014\u00a0 | |||||||
Previous Term Loans | \u2014\u00a0 | 314,000\u00a0 | |||||||||
Class A Notes | 38,336\u00a0 | 50,054\u00a0 | |||||||||
Class B Notes | 25,558\u00a0 | 33,369\u00a0 | |||||||||
| Unamortized debt issuance costs and debt discount | (16,695) | (12,311) | |||||||||
| Total debt | 370,168\u00a0 | 385,112\u00a0 | |||||||||
| Less current portion of long-term debt: | (22,014) | (68,523) | |||||||||
| Long-term debt | $ | 348,154\u00a0 | $ | 316,589\u00a0 |
| (in thousands) | 2027 | 2028 | 2029 | 2030 | 2031 | Total | ||||||||||||||||||||||||||||||||
Term Loan | $ | 8,125\u00a0 | $ | 14,219\u00a0 | $ | 16,250\u00a0 | $ | 16,250\u00a0 | $ | 268,125\u00a0 | $ | 322,969\u00a0 | ||||||||||||||||||||||||||
| Class A Notes | 10,592\u00a0 | 8,650\u00a0 | 19,094\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 38,336\u00a0 | ||||||||||||||||||||||||||||||||
| Class B Notes | 7,062\u00a0 | 5,767\u00a0 | 12,729\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 25,558\u00a0 | ||||||||||||||||||||||||||||||||
| Total obligations | $ | 25,779\u00a0 | $ | 28,636\u00a0 | $ | 48,073\u00a0 | $ | 16,250\u00a0 | $ | 268,125\u00a0 | $ | 386,863\u00a0 |
As of June\u00a030, 2026 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 22,853\u00a0 | $ | 22,853\u00a0 |
As of June 30, 2025 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | |||||||||||||||||||||||
Money market funds | $ | 322\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 322\u00a0 | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 78,657\u00a0 | $ | 78,657\u00a0 |
| June 30, 2026 | |||||
Tranche 1 | |||||
Stock price(1) | $ | 0.84\u00a0 | |||
| Exercise price | $ | 3.00\u00a0 | |||
Expected volatility | 99.17\u00a0 | % | |||
| Risk-free interest rate | 4.07\u00a0 | % | |||
Expected dividend-yield | \u2014\u00a0 | % | |||
Expected life | 3.29 years | ||||
Fair value per warrant | $ | 0.34\u00a0 |
| June 30, 2025 | ||||||||||||||
Tranche 1 | Tranche 2 | Tranche 3 | Tranche 4 | |||||||||||
Stock price(1) | $ | 2.38\u00a0 | $ | 2.38\u00a0 | $ | 2.38\u00a0 | $ | 2.38\u00a0 | ||||||
| Exercise price | $ | 3.00\u00a0 | $ | 3.00\u00a0 | $ | 3.00\u00a0 | $ | 3.00\u00a0 | ||||||
Expected volatility | 109.98\u00a0 | % | 103.31\u00a0 | % | 103.31\u00a0 | % | 103.31\u00a0 | % | ||||||
Risk-free interest rate | 3.68\u00a0 | % | 3.75\u00a0 | % | 3.85\u00a0 | % | 3.95\u00a0 | % | ||||||
Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | ||||||
Expected life | 4.29 years | 5.29 years | 6.29 years | 7.29 years | ||||||||||
Fair value per warrant | $ | 1.75\u00a0 | $ | 1.81\u00a0 | $ | 1.92\u00a0 | $ | 2.00\u00a0 |
| June 30, 2026 | |||||||||||
| Tranche A | Tranche B | Tranche C | |||||||||
Stock price(1) | $ | 0.84\u00a0 | $ | 0.84\u00a0 | $ | 0.84\u00a0 | |||||
| Exercise price | $ | 0.01\u00a0 | $ | 3.92\u00a0 | $ | 5.50\u00a0 | |||||
| Expected volatility | 102.52\u00a0 | % | 102.52\u00a0 | % | 102.52\u00a0 | % | |||||
| Risk-free interest rate | 4.31\u00a0 | % | 4.31\u00a0 | % | 4.31\u00a0 | % | |||||
| Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | |||||
| Expected life | 8.62 years | 8.62 years | 8.62 years | ||||||||
| Fair value per warrant | $ | 0.84\u00a0 | $ | 0.65\u00a0 | $ | 0.62\u00a0 |
| June 30, 2025 | |||||||||||
| Tranche A | Tranche B | Tranche C | |||||||||
Stock price(1) | $ | 2.38\u00a0 | $ | 2.38\u00a0 | $ | 2.38\u00a0 | |||||
| Exercise price | $ | 0.01\u00a0 | $ | 3.92\u00a0 | $ | 5.50\u00a0 | |||||
Expected volatility | 103.31\u00a0 | % | 103.31\u00a0 | % | 103.31\u00a0 | % | |||||
Risk-free interest rate | 4.18\u00a0 | % | 4.18\u00a0 | % | 4.18\u00a0 | % | |||||
Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | |||||
Expected life | 9.62 years | 9.62 years | 9.62 years | ||||||||
Fair value per warrant | $ | 2.38\u00a0 | $ | 2.11\u00a0 | $ | 2.06\u00a0 |
| (in thousands) | Warrant Liability | ||||
| Balance as of June 30, 2024 | $ | \u2014\u00a0 | |||
| Issuance of Eleventh Amendment Warrants | 8,628\u00a0 | ||||
| Issuance of Senior Non-Convertible Preferred Stock Warrants | 128,953\u00a0 | ||||
| Change in fair value | (58,924) | ||||
Balance as of June\u00a030, 2025 | 78,657\u00a0 | ||||
| Change in fair value | (51,563) | ||||
| Cancellation of Eleventh Amendment Tranche 2-4 Warrants | (4,241) | ||||
Balance as of June\u00a030, 2026 | $ | 22,853\u00a0 |
As of June\u00a030, 2026 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 22,853\u00a0 | $ | 22,853\u00a0 |
As of June 30, 2025 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | |||||||||||||||||||||||
Money market funds | $ | 322\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 322\u00a0 | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 78,657\u00a0 | $ | 78,657\u00a0 |
| June 30, 2026 | |||||
Tranche 1 | |||||
Stock price(1) | $ | 0.84\u00a0 | |||
| Exercise price | $ | 3.00\u00a0 | |||
Expected volatility | 99.17\u00a0 | % | |||
| Risk-free interest rate | 4.07\u00a0 | % | |||
Expected dividend-yield | \u2014\u00a0 | % | |||
Expected life | 3.29 years | ||||
Fair value per warrant | $ | 0.34\u00a0 |
| June 30, 2025 | ||||||||||||||
Tranche 1 | Tranche 2 | Tranche 3 | Tranche 4 | |||||||||||
Stock price(1) | $ | 2.38\u00a0 | $ | 2.38\u00a0 | $ | 2.38\u00a0 | $ | 2.38\u00a0 | ||||||
| Exercise price | $ | 3.00\u00a0 | $ | 3.00\u00a0 | $ | 3.00\u00a0 | $ | 3.00\u00a0 | ||||||
Expected volatility | 109.98\u00a0 | % | 103.31\u00a0 | % | 103.31\u00a0 | % | 103.31\u00a0 | % | ||||||
Risk-free interest rate | 3.68\u00a0 | % | 3.75\u00a0 | % | 3.85\u00a0 | % | 3.95\u00a0 | % | ||||||
Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | ||||||
Expected life | 4.29 years | 5.29 years | 6.29 years | 7.29 years | ||||||||||
Fair value per warrant | $ | 1.75\u00a0 | $ | 1.81\u00a0 | $ | 1.92\u00a0 | $ | 2.00\u00a0 |
| June 30, 2026 | |||||||||||
| Tranche A | Tranche B | Tranche C | |||||||||
Stock price(1) | $ | 0.84\u00a0 | $ | 0.84\u00a0 | $ | 0.84\u00a0 | |||||
| Exercise price | $ | 0.01\u00a0 | $ | 3.92\u00a0 | $ | 5.50\u00a0 | |||||
| Expected volatility | 102.52\u00a0 | % | 102.52\u00a0 | % | 102.52\u00a0 | % | |||||
| Risk-free interest rate | 4.31\u00a0 | % | 4.31\u00a0 | % | 4.31\u00a0 | % | |||||
| Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | |||||
| Expected life | 8.62 years | 8.62 years | 8.62 years | ||||||||
| Fair value per warrant | $ | 0.84\u00a0 | $ | 0.65\u00a0 | $ | 0.62\u00a0 |
| June 30, 2025 | |||||||||||
| Tranche A | Tranche B | Tranche C | |||||||||
Stock price(1) | $ | 2.38\u00a0 | $ | 2.38\u00a0 | $ | 2.38\u00a0 | |||||
| Exercise price | $ | 0.01\u00a0 | $ | 3.92\u00a0 | $ | 5.50\u00a0 | |||||
Expected volatility | 103.31\u00a0 | % | 103.31\u00a0 | % | 103.31\u00a0 | % | |||||
Risk-free interest rate | 4.18\u00a0 | % | 4.18\u00a0 | % | 4.18\u00a0 | % | |||||
Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | |||||
Expected life | 9.62 years | 9.62 years | 9.62 years | ||||||||
Fair value per warrant | $ | 2.38\u00a0 | $ | 2.11\u00a0 | $ | 2.06\u00a0 |
| (in thousands) | Warrant Liability | ||||
| Balance as of June 30, 2024 | $ | \u2014\u00a0 | |||
| Issuance of Eleventh Amendment Warrants | 8,628\u00a0 | ||||
| Issuance of Senior Non-Convertible Preferred Stock Warrants | 128,953\u00a0 | ||||
| Change in fair value | (58,924) | ||||
Balance as of June\u00a030, 2025 | 78,657\u00a0 | ||||
| Change in fair value | (51,563) | ||||
| Cancellation of Eleventh Amendment Tranche 2-4 Warrants | (4,241) | ||||
Balance as of June\u00a030, 2026 | $ | 22,853\u00a0 |
| ESPP | 159\u00a0 | |||||||
| Stock awards outstanding under 2020 Plan | 20,502,904\u00a0 | |||||||
| Stock awards available for grant under 2020 Plan | 1,968,883\u00a0 | |||||||
| Options outstanding under 2003 Plan | 423,399\u00a0 | |||||||
| Total | 22,895,345\u00a0 |
| Year Ended June 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Share-based compensation related to: | ||||||||||||||||||||
| Equity classified stock options | $ | 283\u00a0 | $ | 1,607\u00a0 | $ | 2,733\u00a0 | ||||||||||||||
Equity classified RSUs | 9,857\u00a0 | 10,070\u00a0 | 7,701\u00a0 | |||||||||||||||||
| Equity classified PSU's | \u2014\u00a0 | \u2014\u00a0 | 33\u00a0 | |||||||||||||||||
Equity classified PVUs | 4,722\u00a0 | 6,680\u00a0 | 3,349\u00a0 | |||||||||||||||||
| Total | $ | 14,862\u00a0 | $ | 18,357\u00a0 | $ | 13,816\u00a0 |
| Number of Options | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (in Years) | Aggregate Intrinsic Value (in Thousands) | |||||||||||
Outstanding\u2014June\u00a030, 2025 | 3,338,025\u00a0 | $ | 12.30\u00a0 | |||||||||||
| Options exercised | \u2014\u00a0 | \u2014\u00a0 | ||||||||||||
| Options forfeited/expired/cancelled | (141,130) | 15.53\u00a0 | ||||||||||||
Outstanding\u2014June\u00a030, 2026 | 3,196,895\u00a0 | $ | 12.16\u00a0 | 4.45 | $ | \u2014\u00a0 | ||||||||
Vested and exercisable\u2014June\u00a030, 2026 | 3,196,895\u00a0 | $ | 12.16\u00a0 | 4.45 | $ | \u2014\u00a0 |
| Number of Restricted Stock Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2025 | 8,389,188\u00a0 | $ | 2.30\u00a0 | ||||||||
| Granted | 5,967,147\u00a0 | 1.73\u00a0 | |||||||||
| Vested | (4,375,083) | 2.28\u00a0 | |||||||||
| Forfeited | (611,931) | 2.08\u00a0 | |||||||||
Unvested as of June\u00a030, 2026 | 9,369,321\u00a0 | $ | 1.96\u00a0 |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 636,666\u00a0 | $ | 1.67\u00a0 | $ | 2.50\u00a0 | August 1, 2025 - August 1, 2030 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 636,668\u00a0 | $ | 1.59\u00a0 | $ | 4.00\u00a0 | August 1, 2025 - August 1, 2030 | 1.14 years - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 636,666\u00a0 | $ | 1.49\u00a0 | $ | 6.00\u00a0 | August 1, 2025 - August 1, 2030 | 1.62 years - 3 years |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 772,027\u00a0 | $ | 3.98\u00a0 | $ | 3.13\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 772,020\u00a0 | $ | 3.75\u00a0 | $ | 6.00\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 772,027\u00a0 | $ | 3.49\u00a0 | $ | 9.00\u00a0 | August 1, 2024 - August 1, 2029 | 1.31 years - 3 years |
Shares Granted August 1, 2025 | Shares Granted August 1, 2024 | |||||||||||||
| Share price as of grant date | $1.74 | $4.01 | ||||||||||||
| Volatility | 104.2% | 88.8% | ||||||||||||
| Risk-free interest rate | 3.7% | 3.8% | ||||||||||||
| Cost of Equity | 15.8% | 12.6% | ||||||||||||
| Dividend yield | \u2014% | \u2014% |
| Number of Price-Vested Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2025 | 7,481,813\u00a0 | $ | 2.11\u00a0 | ||||||||
| Granted | 1,910,000\u00a0 | $ | 1.58\u00a0 | ||||||||
| Vested | (755,544) | $ | 2.16\u00a0 | ||||||||
| Forfeited | (276,182) | $ | 2.33\u00a0 | ||||||||
Unvested as of June\u00a030, 2026 | 8,360,087\u00a0 | $ | 1.96\u00a0 |
| ESPP | 159\u00a0 | |||||||
| Stock awards outstanding under 2020 Plan | 20,502,904\u00a0 | |||||||
| Stock awards available for grant under 2020 Plan | 1,968,883\u00a0 | |||||||
| Options outstanding under 2003 Plan | 423,399\u00a0 | |||||||
| Total | 22,895,345\u00a0 |
| Year Ended June 30, | ||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Share-based compensation related to: | ||||||||||||||||||||
| Equity classified stock options | $ | 283\u00a0 | $ | 1,607\u00a0 | $ | 2,733\u00a0 | ||||||||||||||
Equity classified RSUs | 9,857\u00a0 | 10,070\u00a0 | 7,701\u00a0 | |||||||||||||||||
| Equity classified PSU's | \u2014\u00a0 | \u2014\u00a0 | 33\u00a0 | |||||||||||||||||
Equity classified PVUs | 4,722\u00a0 | 6,680\u00a0 | 3,349\u00a0 | |||||||||||||||||
| Total | $ | 14,862\u00a0 | $ | 18,357\u00a0 | $ | 13,816\u00a0 |
| Number of Options | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (in Years) | Aggregate Intrinsic Value (in Thousands) | |||||||||||
Outstanding\u2014June\u00a030, 2025 | 3,338,025\u00a0 | $ | 12.30\u00a0 | |||||||||||
| Options exercised | \u2014\u00a0 | \u2014\u00a0 | ||||||||||||
| Options forfeited/expired/cancelled | (141,130) | 15.53\u00a0 | ||||||||||||
Outstanding\u2014June\u00a030, 2026 | 3,196,895\u00a0 | $ | 12.16\u00a0 | 4.45 | $ | \u2014\u00a0 | ||||||||
Vested and exercisable\u2014June\u00a030, 2026 | 3,196,895\u00a0 | $ | 12.16\u00a0 | 4.45 | $ | \u2014\u00a0 |
| Number of Restricted Stock Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2025 | 8,389,188\u00a0 | $ | 2.30\u00a0 | ||||||||
| Granted | 5,967,147\u00a0 | 1.73\u00a0 | |||||||||
| Vested | (4,375,083) | 2.28\u00a0 | |||||||||
| Forfeited | (611,931) | 2.08\u00a0 | |||||||||
Unvested as of June\u00a030, 2026 | 9,369,321\u00a0 | $ | 1.96\u00a0 |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 636,666\u00a0 | $ | 1.67\u00a0 | $ | 2.50\u00a0 | August 1, 2025 - August 1, 2030 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 636,668\u00a0 | $ | 1.59\u00a0 | $ | 4.00\u00a0 | August 1, 2025 - August 1, 2030 | 1.14 years - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 636,666\u00a0 | $ | 1.49\u00a0 | $ | 6.00\u00a0 | August 1, 2025 - August 1, 2030 | 1.62 years - 3 years |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 772,027\u00a0 | $ | 3.98\u00a0 | $ | 3.13\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 772,020\u00a0 | $ | 3.75\u00a0 | $ | 6.00\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 772,027\u00a0 | $ | 3.49\u00a0 | $ | 9.00\u00a0 | August 1, 2024 - August 1, 2029 | 1.31 years - 3 years |
Shares Granted August 1, 2025 | Shares Granted August 1, 2024 | |||||||||||||
| Share price as of grant date | $1.74 | $4.01 | ||||||||||||
| Volatility | 104.2% | 88.8% | ||||||||||||
| Risk-free interest rate | 3.7% | 3.8% | ||||||||||||
| Cost of Equity | 15.8% | 12.6% | ||||||||||||
| Dividend yield | \u2014% | \u2014% |
| Number of Price-Vested Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2025 | 7,481,813\u00a0 | $ | 2.11\u00a0 | ||||||||
| Granted | 1,910,000\u00a0 | $ | 1.58\u00a0 | ||||||||
| Vested | (755,544) | $ | 2.16\u00a0 | ||||||||
| Forfeited | (276,182) | $ | 2.33\u00a0 | ||||||||
Unvested as of June\u00a030, 2026 | 8,360,087\u00a0 | $ | 1.96\u00a0 |
| Year Ended June 30, | |||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
| Current income taxes: | |||||||||||||||||
| Federal | $ | 273\u00a0 | $ | (1,527) | $ | 2,523\u00a0 | |||||||||||
| State | 1,949\u00a0 | 952\u00a0 | 1,286\u00a0 | ||||||||||||||
| Total | 2,222\u00a0 | (575) | 3,809\u00a0 | ||||||||||||||
| Deferred income taxes: | |||||||||||||||||
| Federal | 5,160\u00a0 | 1,192\u00a0 | (2,805) | ||||||||||||||
| State | 6,716\u00a0 | 314\u00a0 | 4,055\u00a0 | ||||||||||||||
| Total | 11,876\u00a0 | 1,506\u00a0 | 1,250\u00a0 | ||||||||||||||
| Income tax expense | $ | 14,098\u00a0 | $ | 931\u00a0 | $ | 5,059\u00a0 | |||||||||||
| Total Federal tax expense (benefit) | $ | 5,433\u00a0 | $ | (335) | $ | (282) | |||||||||||
| Total State tax expense | $ | 8,665\u00a0 | $ | 1,266\u00a0 | $ | 5,341\u00a0 |
| Year Ended June 30, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||||||||||||||||||||
| Amount | Percent | Amount | Percent | Amount | Percent | ||||||||||||||||||||||||||||||
| Federal statutory income tax rate | $16,020 | 21.0% | $10,187 | 21.0% | $(6,104) | 21.0% | |||||||||||||||||||||||||||||
| State income taxes. net of federal effect | 8,256 | 10.8% | 1,065 | 2.2% | 5,422 | (18.7)% | |||||||||||||||||||||||||||||
| Domestic federal | |||||||||||||||||||||||||||||||||||
| Tax credits | |||||||||||||||||||||||||||||||||||
| Credit for research activities | (260) | (0.3)% | (1,596) | (3.3)% | \u2014 | \u2014 | |||||||||||||||||||||||||||||
| Work opportunity credit | (239) | (0.3)% | (1,601) | (3.3)% | (269) | 0.9% | |||||||||||||||||||||||||||||
| Changes in valuation allowance | 94 | 0.1% | 3,365 | 6.9% | 5,204 | (17.9)% | |||||||||||||||||||||||||||||
| Nontaxable or nondeductible items | |||||||||||||||||||||||||||||||||||
| Executive officer compensation | 836 | 1.1% | 1,772 | 3.7% | 122 | (0.4)% | |||||||||||||||||||||||||||||
| Equity compensation | 641 | 0.8% | (1,776) | (3.7)% | 198 | (0.7)% | |||||||||||||||||||||||||||||
| Transaction costs | \u2014 | \u2014% | 859 | 1.8% | \u2014 | \u2014 | |||||||||||||||||||||||||||||
| Warrant mark-to-market | (11,719) | (15.3)% | (12,500) | (25.8)% | \u2014 | \u2014 | |||||||||||||||||||||||||||||
| Other | 384 | 0.5% | 744 | 1.6% | 486 | (1.6)% | |||||||||||||||||||||||||||||
| Changes in unrecognized tax benefits | 85 | 0.1% | 412 | 0.8% | \u2014 | \u2014 | |||||||||||||||||||||||||||||
| Income tax expense and effective tax rate | $14,098 | 18.5% | $931 | 1.9% | $5,059 | (17.4)% |
| (in thousands) | 2026 | 2025 | |||||||||
| Deferred tax assets: | |||||||||||
| \u00a0\u00a0Accruals and other | $ | 13,523\u00a0 | $ | 11,165\u00a0 | |||||||
| Lease liability | 7,124\u00a0 | 8,187\u00a0 | |||||||||
| \u00a0\u00a0Interest expense limitation | 80,000\u00a0 | 75,708\u00a0 | |||||||||
| \u00a0\u00a0Net operating losses | 147,178\u00a0 | 150,643\u00a0 | |||||||||
| \u00a0\u00a0Credit carryforward | 4,993\u00a0 | 5,068\u00a0 | |||||||||
| Basis difference in fixed and amortizable assets | 11,708\u00a0 | 13,289\u00a0 | |||||||||
| Total deferred tax assets | 264,526\u00a0 | 264,060\u00a0 | |||||||||
Less: Valuation allowance | (30,370) | (28,083) | |||||||||
Deferred tax assets, net of valuation allowance | $ | 234,156\u00a0 | $ | 235,977\u00a0 | |||||||
| Deferred tax liabilities: | |||||||||||
| \u00a0\u00a0Commissions receivable | $ | (275,816) | $ | (266,600) | |||||||
| Lease right-of-use asset | (5,627) | (6,617) | |||||||||
Other | (2,166) | (632) | |||||||||
\u00a0\u00a0Total deferred tax liabilities | (283,609) | (273,849) | |||||||||
| Net long-term deferred tax liabilities | $ | (49,453) | $ | (37,872) |
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Federal | $ | (500) | $ | 1,850\u00a0 | $ | 217\u00a0 | ||||||||||||||
| State | 308\u00a0 | 1,306\u00a0 | 377\u00a0 | |||||||||||||||||
| Total income taxes paid (net of refunds) | $ | (192) | $ | 3,156\u00a0 | $ | 594\u00a0 |
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| State | ||||||||||||||||||||
| Alabama | 65\u00a0 | * | \u2014\u00a0 | |||||||||||||||||
| Georgia | \u2014\u00a0 | 227\u00a0 | \u2014\u00a0 | |||||||||||||||||
| Illinois | \u2014\u00a0 | 201\u00a0 | * | |||||||||||||||||
| Louisiana | 88\u00a0 | * | 55\u00a0 | |||||||||||||||||
| Massachusetts | 12\u00a0 | * | * | |||||||||||||||||
| North Carolina | 34\u00a0 | \u2014\u00a0 | \u2014\u00a0 | |||||||||||||||||
| Oklahoma | 20\u00a0 | * | \u2014\u00a0 | |||||||||||||||||
| Pennsylvania | 46\u00a0 | 382\u00a0 | 237\u00a0 | |||||||||||||||||
| Tennessee | 21\u00a0 | \u2014\u00a0 | \u2014\u00a0 |
| Year Ended June 30, | ||||||||
(in thousands) | 2026 | 2025 | ||||||
| Balance at beginning of year | $ | 399\u00a0 | $ | \u2014\u00a0 | ||||
Additions for UTP\u2019s of prior years | 65\u00a0 | 350\u00a0 | ||||||
Decreases for UTP\u2019s of prior years | \u2014\u00a0 | \u2014\u00a0 | ||||||
Additions for UTP\u2019s of current year | \u2014\u00a0 | 49\u00a0 | ||||||
Decreases related to audit settlements | \u2014\u00a0 | \u2014\u00a0 | ||||||
| Balance at end of year | $ | 464\u00a0 | $ | 399\u00a0 |
| Year Ended June 30, | |||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
| Current income taxes: | |||||||||||||||||
| Federal | $ | 273\u00a0 | $ | (1,527) | $ | 2,523\u00a0 | |||||||||||
| State | 1,949\u00a0 | 952\u00a0 | 1,286\u00a0 | ||||||||||||||
| Total | 2,222\u00a0 | (575) | 3,809\u00a0 | ||||||||||||||
| Deferred income taxes: | |||||||||||||||||
| Federal | 5,160\u00a0 | 1,192\u00a0 | (2,805) | ||||||||||||||
| State | 6,716\u00a0 | 314\u00a0 | 4,055\u00a0 | ||||||||||||||
| Total | 11,876\u00a0 | 1,506\u00a0 | 1,250\u00a0 | ||||||||||||||
| Income tax expense | $ | 14,098\u00a0 | $ | 931\u00a0 | $ | 5,059\u00a0 | |||||||||||
| Total Federal tax expense (benefit) | $ | 5,433\u00a0 | $ | (335) | $ | (282) | |||||||||||
| Total State tax expense | $ | 8,665\u00a0 | $ | 1,266\u00a0 | $ | 5,341\u00a0 |
| Year Ended June 30, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||||||||||||||||||||
| Amount | Percent | Amount | Percent | Amount | Percent | ||||||||||||||||||||||||||||||
| Federal statutory income tax rate | $16,020 | 21.0% | $10,187 | 21.0% | $(6,104) | 21.0% | |||||||||||||||||||||||||||||
| State income taxes. net of federal effect | 8,256 | 10.8% | 1,065 | 2.2% | 5,422 | (18.7)% | |||||||||||||||||||||||||||||
| Domestic federal | |||||||||||||||||||||||||||||||||||
| Tax credits | |||||||||||||||||||||||||||||||||||
| Credit for research activities | (260) | (0.3)% | (1,596) | (3.3)% | \u2014 | \u2014 | |||||||||||||||||||||||||||||
| Work opportunity credit | (239) | (0.3)% | (1,601) | (3.3)% | (269) | 0.9% | |||||||||||||||||||||||||||||
| Changes in valuation allowance | 94 | 0.1% | 3,365 | 6.9% | 5,204 | (17.9)% | |||||||||||||||||||||||||||||
| Nontaxable or nondeductible items | |||||||||||||||||||||||||||||||||||
| Executive officer compensation | 836 | 1.1% | 1,772 | 3.7% | 122 | (0.4)% | |||||||||||||||||||||||||||||
| Equity compensation | 641 | 0.8% | (1,776) | (3.7)% | 198 | (0.7)% | |||||||||||||||||||||||||||||
| Transaction costs | \u2014 | \u2014% | 859 | 1.8% | \u2014 | \u2014 | |||||||||||||||||||||||||||||
| Warrant mark-to-market | (11,719) | (15.3)% | (12,500) | (25.8)% | \u2014 | \u2014 | |||||||||||||||||||||||||||||
| Other | 384 | 0.5% | 744 | 1.6% | 486 | (1.6)% | |||||||||||||||||||||||||||||
| Changes in unrecognized tax benefits | 85 | 0.1% | 412 | 0.8% | \u2014 | \u2014 | |||||||||||||||||||||||||||||
| Income tax expense and effective tax rate | $14,098 | 18.5% | $931 | 1.9% | $5,059 | (17.4)% |
| (in thousands) | 2026 | 2025 | |||||||||
| Deferred tax assets: | |||||||||||
| \u00a0\u00a0Accruals and other | $ | 13,523\u00a0 | $ | 11,165\u00a0 | |||||||
| Lease liability | 7,124\u00a0 | 8,187\u00a0 | |||||||||
| \u00a0\u00a0Interest expense limitation | 80,000\u00a0 | 75,708\u00a0 | |||||||||
| \u00a0\u00a0Net operating losses | 147,178\u00a0 | 150,643\u00a0 | |||||||||
| \u00a0\u00a0Credit carryforward | 4,993\u00a0 | 5,068\u00a0 | |||||||||
| Basis difference in fixed and amortizable assets | 11,708\u00a0 | 13,289\u00a0 | |||||||||
| Total deferred tax assets | 264,526\u00a0 | 264,060\u00a0 | |||||||||
Less: Valuation allowance | (30,370) | (28,083) | |||||||||
Deferred tax assets, net of valuation allowance | $ | 234,156\u00a0 | $ | 235,977\u00a0 | |||||||
| Deferred tax liabilities: | |||||||||||
| \u00a0\u00a0Commissions receivable | $ | (275,816) | $ | (266,600) | |||||||
| Lease right-of-use asset | (5,627) | (6,617) | |||||||||
Other | (2,166) | (632) | |||||||||
\u00a0\u00a0Total deferred tax liabilities | (283,609) | (273,849) | |||||||||
| Net long-term deferred tax liabilities | $ | (49,453) | $ | (37,872) |
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| Federal | $ | (500) | $ | 1,850\u00a0 | $ | 217\u00a0 | ||||||||||||||
| State | 308\u00a0 | 1,306\u00a0 | 377\u00a0 | |||||||||||||||||
| Total income taxes paid (net of refunds) | $ | (192) | $ | 3,156\u00a0 | $ | 594\u00a0 |
| (in thousands) | 2026 | 2025 | 2024 | |||||||||||||||||
| State | ||||||||||||||||||||
| Alabama | 65\u00a0 | * | \u2014\u00a0 | |||||||||||||||||
| Georgia | \u2014\u00a0 | 227\u00a0 | \u2014\u00a0 | |||||||||||||||||
| Illinois | \u2014\u00a0 | 201\u00a0 | * | |||||||||||||||||
| Louisiana | 88\u00a0 | * | 55\u00a0 | |||||||||||||||||
| Massachusetts | 12\u00a0 | * | * | |||||||||||||||||
| North Carolina | 34\u00a0 | \u2014\u00a0 | \u2014\u00a0 | |||||||||||||||||
| Oklahoma | 20\u00a0 | * | \u2014\u00a0 | |||||||||||||||||
| Pennsylvania | 46\u00a0 | 382\u00a0 | 237\u00a0 | |||||||||||||||||
| Tennessee | 21\u00a0 | \u2014\u00a0 | \u2014\u00a0 |
| Year Ended June 30, | ||||||||
(in thousands) | 2026 | 2025 | ||||||
| Balance at beginning of year | $ | 399\u00a0 | $ | \u2014\u00a0 | ||||
Additions for UTP\u2019s of prior years | 65\u00a0 | 350\u00a0 | ||||||
Decreases for UTP\u2019s of prior years | \u2014\u00a0 | \u2014\u00a0 | ||||||
Additions for UTP\u2019s of current year | \u2014\u00a0 | 49\u00a0 | ||||||
Decreases related to audit settlements | \u2014\u00a0 | \u2014\u00a0 | ||||||
| Balance at end of year | $ | 464\u00a0 | $ | 399\u00a0 |
| Year Ended June 30, | |||||||||||||||||
(in thousands, except per share amounts) | 2026 | 2025 | 2024 | ||||||||||||||
| Numerator: | |||||||||||||||||
| Net income (loss) attributable to common shareholders, basic | $ | (11,649) | $ | 25,032\u00a0 | $ | (34,125) | |||||||||||
| \u2014\u00a0 | (22,607) | \u2014\u00a0 | |||||||||||||||
| Net income (loss) attributable to common shareholders, diluted | (11,649) | 2,425\u00a0 | (34,125) | ||||||||||||||
| Denominator: | |||||||||||||||||
| Weighted-average common stock outstanding, basic | 188,174\u00a0 | 176,148\u00a0 | 168,519\u00a0 | ||||||||||||||
Stock options outstanding to purchase shares of common stock including unvested RSUs and from the ESPP(2) | \u2014\u00a0 | 4,458\u00a0 | \u2014\u00a0 | ||||||||||||||
| Dilutive effect of warrants to purchase common stock | \u2014\u00a0 | 1,289\u00a0 | \u2014\u00a0 | ||||||||||||||
Weighted-average common stock outstanding, diluted | 188,174\u00a0 | 181,895\u00a0 | 168,519\u00a0 | ||||||||||||||
| Net income (loss) per share\u2014basic: | $ | (0.06) | $ | 0.14\u00a0 | $ | (0.20) | |||||||||||
| Net income (loss) per share\u2014diluted: | $ | (0.06) | $ | 0.01\u00a0 | $ | (0.20) |
| Year Ended June 30, | |||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
Stock options outstanding to purchase shares of common stock, unvested RSUs and shares from the ESPP | 12,817\u00a0 | 3,799\u00a0 | 12,204\u00a0 |
| Year Ended June 30, | |||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
Shares subject to outstanding PVUs | 8,463\u00a0 | 7,437\u00a0 | 6,243\u00a0 | ||||||||||||||
| Year Ended June 30, | |||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
| Warrants to purchase shares of common stock | 21,843\u00a0 | 8,932\u00a0 | \u2014\u00a0 | ||||||||||||||
| Year Ended June 30, | |||||||||||||||||
(in thousands, except per share amounts) | 2026 | 2025 | 2024 | ||||||||||||||
| Numerator: | |||||||||||||||||
| Net income (loss) attributable to common shareholders, basic | $ | (11,649) | $ | 25,032\u00a0 | $ | (34,125) | |||||||||||
| \u2014\u00a0 | (22,607) | \u2014\u00a0 | |||||||||||||||
| Net income (loss) attributable to common shareholders, diluted | (11,649) | 2,425\u00a0 | (34,125) | ||||||||||||||
| Denominator: | |||||||||||||||||
| Weighted-average common stock outstanding, basic | 188,174\u00a0 | 176,148\u00a0 | 168,519\u00a0 | ||||||||||||||
Stock options outstanding to purchase shares of common stock including unvested RSUs and from the ESPP(2) | \u2014\u00a0 | 4,458\u00a0 | \u2014\u00a0 | ||||||||||||||
| Dilutive effect of warrants to purchase common stock | \u2014\u00a0 | 1,289\u00a0 | \u2014\u00a0 | ||||||||||||||
Weighted-average common stock outstanding, diluted | 188,174\u00a0 | 181,895\u00a0 | 168,519\u00a0 | ||||||||||||||
| Net income (loss) per share\u2014basic: | $ | (0.06) | $ | 0.14\u00a0 | $ | (0.20) | |||||||||||
| Net income (loss) per share\u2014diluted: | $ | (0.06) | $ | 0.01\u00a0 | $ | (0.20) |
| Year Ended June 30, | |||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
Stock options outstanding to purchase shares of common stock, unvested RSUs and shares from the ESPP | 12,817\u00a0 | 3,799\u00a0 | 12,204\u00a0 |
| Year Ended June 30, | |||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
Shares subject to outstanding PVUs | 8,463\u00a0 | 7,437\u00a0 | 6,243\u00a0 | ||||||||||||||
| Year Ended June 30, | |||||||||||||||||
| (in thousands) | 2026 | 2025 | 2024 | ||||||||||||||
| Warrants to purchase shares of common stock | 21,843\u00a0 | 8,932\u00a0 | \u2014\u00a0 | ||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 568,234\u00a0 | $ | 844,103\u00a0 | $ | 185,935\u00a0 | $ | 1,598,272\u00a0 | |||||||||||||||
| Intersegment revenue | 7,713\u00a0 | 832\u00a0 | 104\u00a0 | 8,649\u00a0 | |||||||||||||||||||
| Total revenue from reportable segments | $ | 575,947\u00a0 | $ | 844,935\u00a0 | $ | 186,039\u00a0 | $ | 1,606,921\u00a0 | |||||||||||||||
All other revenue (1) | 20,227\u00a0 | ||||||||||||||||||||||
| Eliminations of intersegment revenues | (8,649) | ||||||||||||||||||||||
| Total consolidated revenue | $ | 1,618,499\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 575,947\u00a0 | $ | 844,935\u00a0 | $ | 186,039\u00a0 | $ | 1,606,921\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (202,587) | (27,306) | (70,250) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (724,907) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (222,977) | (7,820) | (87,773) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (1,356) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (2,357) | (58,063) | (1,004) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 148,026\u00a0 | $ | 25,483\u00a0 | $ | 27,012\u00a0 | $ | 200,521\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 13,336\u00a0 | ||||||||||||||||||||||
Corporate (5) | (104,725) | ||||||||||||||||||||||
| Share-based compensation expense | (14,862) | ||||||||||||||||||||||
Transaction costs (6) | (2,112) | ||||||||||||||||||||||
| Depreciation and amortization | (17,489) | ||||||||||||||||||||||
Impairment of equity-method investment (7) | (1,000) | ||||||||||||||||||||||
| Loss on extinguishment of debt | (8,659) | ||||||||||||||||||||||
| Change in fair value of warrants | 55,804\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (44,527) | ||||||||||||||||||||||
Income before income tax expense | $ | 76,287\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 593,335\u00a0 | $ | 742,338\u00a0 | $ | 172,895\u00a0 | $ | 1,508,568\u00a0 | |||||||||||||||
| Intersegment revenue | 7,058\u00a0 | 367\u00a0 | 83\u00a0 | 7,508\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 600,393\u00a0 | $ | 742,705\u00a0 | $ | 172,978\u00a0 | $ | 1,516,076\u00a0 | |||||||||||||||
All other revenue (1) | 18,026\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (7,508) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,526,594\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 600,393\u00a0 | $ | 742,705\u00a0 | $ | 172,978\u00a0 | $ | 1,516,076\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (201,933) | (25,163) | (65,047) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (625,389) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (234,335) | (8,038) | (80,269) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (2,187) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (2,454) | (56,541) | (993) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 161,671\u00a0 | $ | 25,387\u00a0 | $ | 26,669\u00a0 | $ | 213,727\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 10,597\u00a0 | ||||||||||||||||||||||
Corporate (5) | (98,070) | ||||||||||||||||||||||
| Share-based compensation expense | (18,357) | ||||||||||||||||||||||
Transaction costs (6) | (14,617) | ||||||||||||||||||||||
| Depreciation and amortization | (20,460) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (240) | ||||||||||||||||||||||
Impairment of long-lived assets | (4,209) | ||||||||||||||||||||||
| Change in fair value of warrants | 59,525\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (79,385) | ||||||||||||||||||||||
| Income before income tax expense (benefit) | $ | 48,511\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 649,232\u00a0 | $ | 478,491\u00a0 | $ | 157,826\u00a0 | $ | 1,285,549\u00a0 | |||||||||||||||
Intersegment revenue | 6,617\u00a0 | 17\u00a0 | 104\u00a0 | 6,738\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 655,849\u00a0 | $ | 478,508\u00a0 | $ | 157,930\u00a0 | $ | 1,292,287\u00a0 | |||||||||||||||
All other revenue (1) | 36,228\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (6,739) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,321,776\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 655,849\u00a0 | $ | 478,508\u00a0 | $ | 157,930\u00a0 | $ | 1,292,287\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (216,348) | (17,438) | (60,017) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (400,821) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (269,867) | (6,260) | (76,513) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (915) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (2,890) | (45,253) | (1,236) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 166,744\u00a0 | $ | 7,821\u00a0 | $ | 20,164\u00a0 | $ | 194,729\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 14,127\u00a0 | ||||||||||||||||||||||
Corporate (5) | (91,863) | ||||||||||||||||||||||
| Share-based compensation expense | (13,816) | ||||||||||||||||||||||
Transaction costs (6) | (13,158) | ||||||||||||||||||||||
| Depreciation and amortization | (24,998) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (536) | ||||||||||||||||||||||
Interest expense, net | (93,551) | ||||||||||||||||||||||
| Loss before income tax expense (benefit) | $ | (29,066) | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 568,234\u00a0 | $ | 844,103\u00a0 | $ | 185,935\u00a0 | $ | 1,598,272\u00a0 | |||||||||||||||
| Intersegment revenue | 7,713\u00a0 | 832\u00a0 | 104\u00a0 | 8,649\u00a0 | |||||||||||||||||||
| Total revenue from reportable segments | $ | 575,947\u00a0 | $ | 844,935\u00a0 | $ | 186,039\u00a0 | $ | 1,606,921\u00a0 | |||||||||||||||
All other revenue (1) | 20,227\u00a0 | ||||||||||||||||||||||
| Eliminations of intersegment revenues | (8,649) | ||||||||||||||||||||||
| Total consolidated revenue | $ | 1,618,499\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 575,947\u00a0 | $ | 844,935\u00a0 | $ | 186,039\u00a0 | $ | 1,606,921\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (202,587) | (27,306) | (70,250) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (724,907) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (222,977) | (7,820) | (87,773) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (1,356) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (2,357) | (58,063) | (1,004) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 148,026\u00a0 | $ | 25,483\u00a0 | $ | 27,012\u00a0 | $ | 200,521\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 13,336\u00a0 | ||||||||||||||||||||||
Corporate (5) | (104,725) | ||||||||||||||||||||||
| Share-based compensation expense | (14,862) | ||||||||||||||||||||||
Transaction costs (6) | (2,112) | ||||||||||||||||||||||
| Depreciation and amortization | (17,489) | ||||||||||||||||||||||
Impairment of equity-method investment (7) | (1,000) | ||||||||||||||||||||||
| Loss on extinguishment of debt | (8,659) | ||||||||||||||||||||||
| Change in fair value of warrants | 55,804\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (44,527) | ||||||||||||||||||||||
Income before income tax expense | $ | 76,287\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 593,335\u00a0 | $ | 742,338\u00a0 | $ | 172,895\u00a0 | $ | 1,508,568\u00a0 | |||||||||||||||
| Intersegment revenue | 7,058\u00a0 | 367\u00a0 | 83\u00a0 | 7,508\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 600,393\u00a0 | $ | 742,705\u00a0 | $ | 172,978\u00a0 | $ | 1,516,076\u00a0 | |||||||||||||||
All other revenue (1) | 18,026\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (7,508) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,526,594\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 600,393\u00a0 | $ | 742,705\u00a0 | $ | 172,978\u00a0 | $ | 1,516,076\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (201,933) | (25,163) | (65,047) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (625,389) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (234,335) | (8,038) | (80,269) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (2,187) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (2,454) | (56,541) | (993) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 161,671\u00a0 | $ | 25,387\u00a0 | $ | 26,669\u00a0 | $ | 213,727\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 10,597\u00a0 | ||||||||||||||||||||||
Corporate (5) | (98,070) | ||||||||||||||||||||||
| Share-based compensation expense | (18,357) | ||||||||||||||||||||||
Transaction costs (6) | (14,617) | ||||||||||||||||||||||
| Depreciation and amortization | (20,460) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (240) | ||||||||||||||||||||||
Impairment of long-lived assets | (4,209) | ||||||||||||||||||||||
| Change in fair value of warrants | 59,525\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (79,385) | ||||||||||||||||||||||
| Income before income tax expense (benefit) | $ | 48,511\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 649,232\u00a0 | $ | 478,491\u00a0 | $ | 157,826\u00a0 | $ | 1,285,549\u00a0 | |||||||||||||||
Intersegment revenue | 6,617\u00a0 | 17\u00a0 | 104\u00a0 | 6,738\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 655,849\u00a0 | $ | 478,508\u00a0 | $ | 157,930\u00a0 | $ | 1,292,287\u00a0 | |||||||||||||||
All other revenue (1) | 36,228\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (6,739) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,321,776\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Total revenue from reportable segments | $ | 655,849\u00a0 | $ | 478,508\u00a0 | $ | 157,930\u00a0 | $ | 1,292,287\u00a0 | |||||||||||||||
Less: | |||||||||||||||||||||||
Cost of commissions and other services revenue | (216,348) | (17,438) | (60,017) | ||||||||||||||||||||
Cost of goods sold - pharmacy revenue | \u2014\u00a0 | (400,821) | \u2014\u00a0 | ||||||||||||||||||||
Marketing expense (1) | (269,867) | (6,260) | (76,513) | ||||||||||||||||||||
Technical development (2) | \u2014\u00a0 | (915) | \u2014\u00a0 | ||||||||||||||||||||
Selling, general, and administrative (3) | (2,890) | (45,253) | (1,236) | ||||||||||||||||||||
| Adjusted Segment EBITDA | $ | 166,744\u00a0 | $ | 7,821\u00a0 | $ | 20,164\u00a0 | $ | 194,729\u00a0 | |||||||||||||||
Reconciliation of total segment Adjusted EBITDA | |||||||||||||||||||||||
All other Adjusted EBITDA (4) | 14,127\u00a0 | ||||||||||||||||||||||
Corporate (5) | (91,863) | ||||||||||||||||||||||
| Share-based compensation expense | (13,816) | ||||||||||||||||||||||
Transaction costs (6) | (13,158) | ||||||||||||||||||||||
| Depreciation and amortization | (24,998) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (536) | ||||||||||||||||||||||
Interest expense, net | (93,551) | ||||||||||||||||||||||
| Loss before income tax expense (benefit) | $ | (29,066) | |||||||||||||||||||||